A migraine-specific adaptation of the Mindfulness-Based Cognitive Therapy (MBCT) program does not improve headache-related impairment among patients with migraine, but does result in reduced headache frequency and improved psychological functioning.
Vitamin D supplementation could reduce headache attacks per month and headache days per month among migraine patients.
Hormone levels in utero may be linked to the risk for developing migraine in adulthood, and risk may differ by sex.
Acupuncture seems better than sham acupuncture for reducing the frequency of migraine attacks, intensity, and responder rate.
Zavegepant is an investigational calcitonin gene-related peptide (CGRP) receptor antagonist.
Celecoxib may be safe and effective for the treatment of acute migraine and migraine-associated symptoms among patients with episodic migraine.
The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up to 3 prophylactic migraine treatments.
Patients report increased depressive symptomatology in the migraine headache phase of a migraine attack.
Researchers conducted a study to assess the effect of galcanezumab on the total pain burden of patients with episodic cluster headache.
The analysis included 64 randomized clinical trials with a total of 46,442 patients.